ClinicalTrials.gg

Program

benmelstobart

Also written as “TQB2450”, “TQB2450 injection” and “Benmelstobart injection combined with Anlotinib hydrochloride capsule”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Endometrial Neoplasms · Triple Negative Breast Neoplasms · Sarcoma, Alveolar Soft Part, led by Sino Biopharmaceutical.

Furthest: phase 3, since Jan 16, 202033 company-led studies, 9 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical339 open or runningphase 3since Jan 16, 2020Feb 26, 2018Dec 2027phase 3 · NCT06475599

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Feb 26, 2018.

  1. May 17, 2021Phase 2 study in Nasopharyngeal CarcinomaNCT04895345 · 25 enrolled · China
  2. Jul 13, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04964479 · 375 enrolled · China
  3. Nov 23, 2021Phase 3 study in Recurrent Platinum-resistant Ovarian CancerNCT05145218 · 405 enrolled · China
  4. Apr 20, 2022Phase 3 study in Advanced Non-squamous Non-small Cell Lung CancerNCT05346952 · 390 enrolled · China
  5. Nov 21, 2022Phase 2 study in Advanced Solid TumorNCT05645315 · 127 enrolled · China
  6. Dec 20, 2022Phase 3 study in Advanced Squamous Non-Small Cell Lung CarcinomaNCT05718167 · 570 planned · China
  7. Jun 13, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05913089 · 58 planned · China
  8. Oct 31, 2023Phase 1 study in Solid TumorNCT06116240 · 135 enrolled · China
  9. Jun 17, 20242 phase 3 studiesNCT06469879, NCT06475599
  10. Jul 4, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06496490 · 270 planned · China
  11. Jan 6, 2025Phase 2 study in Gastroesophageal AdenocarcinomaNCT06767800 · 204 planned · China
  12. Mar 19, 2025Phase 2 study in Extensive Stage Small Cell Lung CancerNCT06897579 · 40 enrolled · China
  13. Apr 17, 2026Phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177 · 33 planned · China
  14. Nov 16, 2026Primary completion moved from 2027-11 to 2028-12Date moved laterphase 2 · +13 months · NCT07548177

Ahead

  1. Dec 2027Primary completion: phase 3 study in Endometrial NeoplasmsNCT06475599
  2. Dec 2028Primary completion: phase 2 study in Sarcoma, Alveolar Soft PartNCT07548177

TargetBeta

CD274 →read by rule
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07548177Sarcoma, Alveolar Soft Part · China2RecruitingDec 202833
NCT06897579Extensive Stage Small Cell Lung Cancer · China2TerminatedApr 15, 202640
NCT06767800Gastroesophageal Adenocarcinoma · China2RecruitingSep 2026204
NCT06496490Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 2026270
NCT06475599Endometrial Neoplasms · China3Not yet recruitingDec 2027420
NCT06469879Small Cell Lung Cancer Limited Stage · China3Not yet recruitingSep 2026358
NCT06116240Solid Tumor · China1Active, not recruitingDec 2023135
NCT05913089Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 202658
NCT05718167Advanced Squamous Non-Small Cell Lung Carcinoma · China3Not yet recruitingOct 2024570
NCT05645315Advanced Solid Tumor · China2UNKNOWNDec 2023127
NCT05346952Advanced Non-squamous Non-small Cell Lung Cancer · China3UNKNOWNDec 2023390
NCT05145218Recurrent Platinum-resistant Ovarian Cancer · China3UNKNOWNOct 2024405
NCT04964479Carcinoma, Non-Small-Cell Lung · China3UNKNOWNDec 2022375
NCT04895345Nasopharyngeal Carcinoma · China2CompletedApr 29, 202425
NCT04809142Advanced Biliary Cancer · China3UNKNOWNMar 18, 2022392
NCT04623333Recurrence · China2UNKNOWNDec 31, 202280
NCT04574284Advanced Endometrial Cancer · China2CompletedNov 9, 2023170
NCT04523272Advanced Renal Cancer · China3Active, not recruitingJun 2025528
NCT04405505Triple Negative Breast Neoplasms · China3UNKNOWNJul 1, 2022332
NCT04325763Carcinoma, Non-Small-Cell Lung · China3UNKNOWNDec 2022315
NCT04306926Advanced Oligometastatic Non-small Cell Lung Cancer · China2UNKNOWNOct 31, 202259
NCT04236362Gynecological Cancer · China2UNKNOWNDec 31, 202190
NCT04234607Extensive Small Cell Lung Cancer · China3UNKNOWNDec 2022738
NCT04002622Recurrence · China2TerminatedJan 21, 20211
NCT03996408Advanced Cholangiocarcinoma · China2UNKNOWNDec 31, 202042
NCT03991975Advanced Acral Malignant Melanoma · China2UNKNOWNMar 31, 202042
NCT03983928Lung Neoplasms · China2UNKNOWNOct 31, 202030
NCT03910127Carcinoma, Non-Small-Cell Lung · China1UNKNOWNDec 31, 202090
NCT03897283Advanced Solid Tumors · China1UNKNOWNJun 30, 202022
NCT03855358Triple Negative Breast Neoplasms · China1UNKNOWNJun 30, 202030
NCT03825705Carcinoma, Hepatocellular · China2UNKNOWNJan 1, 202160
NCT03800706Safety and Effectiveness · China2UNKNOWNJun 30, 202185
NCT03460457Neoplasms1UNKNOWNMar 15, 201950

How it is read

Names in the registry

  • “TQB2450”, 18 entries
  • “TQB2450 injection”, 4 entries
  • “Benmelstobart injection combined with Anlotinib hydrochloride capsule”, 1 entry
  • “Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule”, 1 entry
  • “TQB2102 for injection combined with Benmelstobart injection”, 1 entry

Codes read as this program: TQB2450.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.